Customizable Alerts – Customizable alarms to indicate high and low glucose levels. There is also a built-in, non-adjustable hypo safety alert set at 55 mg/dL, that may provide extra peace of mind to both parents and the patients themselves.
CGM in full color – The first CGM-enabled pump with a high-contrast color screen with color-coded trend arrows to show where glucose is heading and how fast, revealing the latest glucose values and trends at a glance.
An accurate, longest-wear sensor – With Mean ARD (Absolute Relative Difference) as the industry standard for measuring CGM accuracy, the Dexcom G4® PLATINUM Sensor 13-percent Mean ARD provides exceptional performance and accuracy for reliable results. Dexcom sensors are the only sensors approved for up to seven days of wear.
One of the smallest introducer needles – The Dexcom G4® PLATINUM Sensor is tiny, round and flexible with one of the smallest introducer needles available.
"It's been our goal as a company to not only develop the best treatment solutions available, but also ensure that every member of the diabetes community, including children, may access these tools," said John Wilson, Worldwide Vice President of Insulin Delivery, Animas. "We're thrilled that the FDA approval of this new indication for the Animas® Vibe® System for the first time now allows children as young as age two access to a CGM-enabled pump."
Expanding the global presence of the Animas® Vibe® System, along with providing solutions for children with diabetes and their parents, has been a top priority for Animas. The Animas® Vibe® System is also currently available to children ages two and older in parts of Europe, Australia, New Zealand, and Canada.

Orders for the Animas® Vibe® System are currently being accepted, with anticipated shipment to patients beginning this month. For more information, visit www.animas.com.

1 Bergenstal et al, Effectiveness of Sensor-Augmented Insulin Pump Therapy in Type 1 Diabetes. The New England Journal of Medicine. 2010; 363(4):311-320.
2 Effectiveness of Continuous Glucose Monitoring in a Clinical Care Environment, Evidence from the JDRF-CGM Trial. Diabetes Care, Vol 33, Number 1, Jan 2010.
Important Safety Information
The Animas® Vibe® Insulin Pump and CGM System is intended for the delivery of insulin and for continuous glucose monitoring (CGM) for the management of insulin-requiring diabetes. The Animas® Vibe® System's CGM, which includes the Dexcom G4® PLATINUM Sensor and Transmitter, is indicated for detecting trends and tracking patterns in persons age 2 and older. The system is intended for single patient use and requires a prescription.

More HCB News